Abstract 4364
Background
Glioblastoma (GBM) is characterized by invasion, heterogeneity and high angiogenesis, conferring a poor prognosis. The aim of our study was to assess serum proteins related to these hallmarks with potential prognostic value in GBM.
Methods
Serum samples from GBM patients (N = 57 pts) were collected before Stupp regimen. We defined as “LT survivors” (LTS) those pts above 36-months survival, and as “ST survivors” (STS) those below 6-months survival. In the discovery cohort (N = 25 pts), 4 pts were identified in each group. A pooled analysis from serum samples of each group was performed by a protein profiling platform based on antibody array technology. Expressed proteins were assessed for differential expression between the two groups. In silico validation by using data obtained from French glioma study at R2 was performed. In situ expression levels from selected proteins involved in tumor progression (TP), cell proliferation (CP), invasion (Inv) and cell death (CD) that significantly correlate (p < 0.05) with OS in gliomas were studied. ELISA analysis against an independent sample set from the validation cohort (n = 32 pts, LTS n = 4, STS n = 7) was used to verify expression levels of the target proteins.
Results
A total of 1000 proteins were analyzed by the array. 214 proteins showed differences in fluorescence intensity more than 10-fold between LTS vs STS. Among them, SMAD4, SMAD5, TWEAK, VEGFR2, WISP1, FGF21, NEUROD1, SFRP3, SFPR4 and Bax were selected since obtained the highest differences in fluorescence intensity and correlated with differential OS outcomes in silico. ELISA validation demonstrated SFRP3 to be upregulated in the STS group (media expression (pg/ml) STS=1849;LTS=1039) (p = 0.018). No statistically significant differences were observed in the expression levels for the other proteins between LTS and STS. In validation cohort, median overall survival according to SFRP3 expression (low/high) was 19.7 months (CI 95% 10.7-28.61) vs 9.42 months (CI 95% 3.11-15.72) respectively, although did not reach statistical significance (p = 0.073).
Conclusions
Higher circulating SFRP3 level has been associated with STS in GBM. Overexpression of serum SFPR3 in GBM may be a surrogate indicator of poorer prognosis. Further studies are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
GEINO.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract
2273 - High performance of serial tumor biopsies in first in human (FIH) phase I trials.
Presenter: Jun Sato
Session: Poster Display session 1
Resources:
Abstract
5933 - Response rates and lesion-level progression patterns of solid tumor patients in an academic phase 1 program: implications for tumor heterogeneity
Presenter: Christopher Chen
Session: Poster Display session 1
Resources:
Abstract
3569 - Clinical Benefit and Response Rate in Early Phase Clinical Trials: First Report from a Single-Institution Study
Presenter: Antonio Marra
Session: Poster Display session 1
Resources:
Abstract
4139 - Patient (pt) selection for immunotherapeutic early-phase clinical trials (ieCTs): a single Phase I Unit experience
Presenter: Matteo Simonelli
Session: Poster Display session 1
Resources:
Abstract
4451 - Improving patient selection for immuno-oncology phase 1 trials: an external validation of five prognostic scores at Claudius Regaud Institute of Toulouse, Oncopôle (IUCT-O).
Presenter: Ghassan Al Darazi
Session: Poster Display session 1
Resources:
Abstract
1696 - Demonstrating the Changing Trends in Phase 1 Clinical Trials
Presenter: Christina Guo
Session: Poster Display session 1
Resources:
Abstract
3202 - Participation of Women in phase 1 oncology clinical trials
Presenter: Laura Vidal
Session: Poster Display session 1
Resources:
Abstract
4518 - Predictors for early trial discontinuation of patients with cancer participating in phase I clinical trials
Presenter: Joeri Douma
Session: Poster Display session 1
Resources:
Abstract
4368 - Safety of Tumor Treating Fields delivery to the torso: Meta analysis from TTFields clinical trials
Presenter: Federica Grosso
Session: Poster Display session 1
Resources:
Abstract